Welcome to our dedicated page for Arrivent Biopharma SEC filings (Ticker: AVBP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ArriVent BioPharma, Inc. (AVBP) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. ArriVent is a Nasdaq-listed, clinical-stage biopharmaceutical company, and its filings offer insight into the development of firmonertinib and its antibody-drug conjugate pipeline, as well as its capital structure and governance.
Through current reports on Form 8-K, ArriVent reports material events such as quarterly financial results, interim and final clinical data updates for firmonertinib in EGFR exon 20 insertion and PACC mutant non-small cell lung cancer (NSCLC), public offerings of common stock and pre-funded warrants, and collaboration agreements. These filings also confirm that ArriVent’s common stock trades on The Nasdaq Stock Market LLC under the symbol AVBP and identify the company as an emerging growth company.
Investors can use this page to review how ArriVent describes its pivotal Phase 3 trials like FURVENT and ALPACCA, its Phase 1b FURTHER study, and regulatory milestones such as FDA Breakthrough Therapy Designation and Orphan Drug Designation for firmonertinib. Filings may also discuss pipeline assets such as ARR-217 (MRG007), a CDH17-targeted ADC, and outline how equity offerings and cash resources are intended to support ongoing research and development.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly identify information on clinical trial status, financial condition, and corporate actions. Real-time updates from EDGAR, along with structured access to 8-Ks and other core filings, allow users to monitor changes in ArriVent’s development programs, financing activities, and governance without manually parsing every page.
ArriVent BioPharma, Inc. is reported as having a significant passive stake held by related Infinitum entities. The filing shows Infinitum Cayman Master Ltd, Infinitum Asset Management LLC and Infinitum Partners GP, LLC each beneficially own 3,418,923 shares, representing 9.99% of the company’s common stock, and each reports sole voting and sole dispositive power over those shares. The statement certifies the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer. The disclosure identifies the three reporting entities as the holders and confirms the position is a material passive stake.
ArriVent BioPharma (AVBP) is a clinical-stage biotech focused on firmonertinib and ADC programs. The company reported strong liquidity with $112.8M cash and $141.7M marketable securities (total ~$254.5M), and completed equity raises including $81.9M from an ATM program and a subsequent $81.1M underwritten offering, and has an undrawn $75M term loan commitment.
Operations show increasing investment in development: a $95.8M net loss and $94.1M net cash used in operating activities for the six months reported, driven by $89.0M of R&D spend and growing G&A. Clinical interim data for firmonertinib cited high response rates (e.g., 79% ORR in one cohort and durable responses; FURTHER interim: 16.0 months PFS and 14.6 months DOR at 240 mg), supporting continued development. The company holds substantial contingent milestone and royalty obligations under its licenses (e.g., up to $765M to Allist and ~$1.17B to Lepu).
ArriVent BioPharma, Inc. disclosed that it issued a press release announcing its financial results for the second quarter ended June 30, 2025. The company furnished that press release as Exhibit 99.1 to this Form 8-K, and also included a Cover Page Interactive Data File as Exhibit 104. The filing states the press release and related information are being furnished and are not to be deemed "filed" under the Securities Exchange Act.
The Form 8-K itself does not include the financial figures or operating metrics; the substantive results are contained in the press release referenced as Exhibit 99.1.
ArriVent BioPharma (Nasdaq: AVBP) furnished an 8-K to disclose positive interim results from its global Phase 1b FURTHER study evaluating first-line firmonertinib monotherapy in patients with EGFR P-loop and α-C-helix compressing (PACC) mutant non-small cell lung cancer (NSCLC).
At the 240 mg dose, investigators observed a median progression-free survival (mPFS) of 16.0 months and a median duration of response of 14.6 months (cut-off 3 Mar 2025). Tumor shrinkage of ≥30%—the study’s threshold for overall response—occurred in 68.2% of first-line patients at 240 mg versus 43.5% at 160 mg. Among patients presenting with brain metastases, 41% achieved a confirmed response and 53% recorded ≥30% tumor reduction, underscoring central-nervous-system activity.
Safety remained favorable: no Grade 4 or 5 treatment-related adverse events (TRAEs) and no treatment discontinuations; the most common TRAEs were diarrhea, elevated hepatic enzymes, rash, stomatitis and dry skin.
Based on these data, AVBP will launch ALPACCA (FURMO-006), a randomized global Phase 3 trial using the 240 mg dose, with first-patient-in targeted for the second half of 2025. The press release detailing the findings is furnished as Exhibit 99.1; information under Item 7.01 is not deemed “filed” for Exchange Act purposes.
ArriVent BioPharma (NASDAQ:AVBP) submitted a routine Form 4 on 28 June 2025 reporting an insider transaction by director Merdad Parsey.
According to the filing, Parsey acquired 15,502 non-qualified stock options on 18 June 2025 at an exercise price of $24.89 per share. The options become exercisable on 18 June 2026 and expire on 17 June 2035. No common shares were sold or purchased outright, and the transaction was reported as direct ownership. After the grant, Parsey holds an additional 15,502 derivative securities linked to AVBP common stock.
No other material changes, sales, or new share ownership percentages were disclosed in this filing.